Search

Effectiveness and Safety of China-Made Omeprazole in Treating Acute Non-Variceal Upper Gastrointestinal Bleeding: A Meta-Analysis

Objective　To systematically evaluate the effectiveness and safety of China-made omeprazole in treating acute non-variceal upper gastrointestinal bleeding. Methods　Such databases as PubMed, MEDLINE, Springer, The Cochrane Library, CNKI, VIP, CBM and WanFang data were searched to collect the randomized controlled trials (RCTs) about China-made omeprazole in treating acute non-variceal upper gastrointestinal bleeding, and the references of included studies were also retrieved. The retrieval time was from inception to December 2012. Two reviewers independently screened the literature according to the inclusion and exclusion criteria, extracted the data, and assessed the quality, and then the meta-analysis was conducted by using RevMan 5.1 software. Results　A total of 11 RCTs were included. Among all 1 075 patients, 544 were in the treatment group, while the other 531 were in the control group. The results of meta-analysis showed that, there were no significant differences in the total effective rate (OR=0.68, 95%CI 0.35 to 1.33, P=0.26) and safety (RR=1.33, 95%CI 0.45 to 3.91, P=0.96) between the China-made omeprazole and imported omeprazole. Conclusion　China-made omeprazole is effective and safe in treating acute non-variceal upper gastrointestinal bleeding in comparison with the imported omeprazole.

康复新液佐助治疗反流性食管炎疗效分析

目的　探讨康复新液联合奥美拉唑、莫沙比利治疗反流性食管炎的疗效。 方法　纳入2011年8月－2012年12月就诊的90例经内镜确诊的反流性食管炎患者，随机分为两组。观察组45例，给予康复新液联合奥美拉唑、莫沙比利治疗；对照组45例，口服奥美拉唑、莫沙比利治疗。两组的疗程均为8周，观察并记录患者临床症状改善情况，复查胃镜，比较两组的显效率及总有效率。 结果　观察组患者8周时显效率为68.89%，总有效率为95.56%；对照组患者8周时显效率为51.11%，总有效率为84.44%。两组显效率及总有效率均有统计学意义（P＜0.05）。结论　康复新液联合奥美拉唑、莫沙必利治疗反流性食管炎具有良好的协同作用，且无明显不良反应，值得临床推广应用。

Thera Peutic Observation on 32 Cases of Gastritis Verrucosa Treated by Radiofrequency under the Guidance of Endoscopy Combined with Drugs

目的：探讨射频配合药物治疗疣状胃炎的疗效。方法:将胃镜诊断为疣状胃炎患者68例随机分为两组，射频配合药物治疗组用射频波25～40W对病灶行一次性“ 烧灼”，术后口服奥美拉唑胶囊4周；药物治疗组使用奥美拉唑治疗4周组作为对照组。两组若幽门螺杆菌(HP)阳性者均给予根除HP治疗。结果：射频配合药物治疗组症状缓解/消失率及疣状病灶消退率明显优于药物治疗组（P＜0.01）。结论：射频配合药物治疗疣状胃炎是一种较理想的、值得推广的有效方法，具有治疗彻底，操作技术简单,使用安全,病灶愈合快,治愈时间短,价格便宜,病人痛苦小等优点。

The Gastrointestinal Protective Effect of Omeprazole on Children Undergoing Thoracoscopic Heart Surgery with Cardiopulmonary Bypass

Objective To investigate the gastrointestinal(GI) protective effect of Omeprazole on children undergoing thoracoscopic heart surgery with cardiopulmonary bypass (CPB). Methods One hundred and twenty seven patients who were scheduled for cardiac surgery with CPB were randomly equally divided into three groups. Group A and B underwent thoracoscopic heart surgery, while the control group underwent conventional heart surgery by sternotomy. Before CPB, group A was treated with Omeprazole 10mg added to the priming solution.? Group B and the control group were treated by adding the same amount of normal saline (to the priming solution). pH and red blood cell count of gastric secretion and serum gastric level (Assay Designs ELISA) were measured at the following intervals: before CPB, 30 minutes into CPB, at termination of CPB,4 and 24 hours after termination of CPB. Results Compare to prior to CBP, the value of the gastric pH in group A was significantly higher (Plt;0.01), and that of group B was significantly lower (Plt;0.05)at the end of CPB. The same value in the control group was significantly lower (Plt;0.05)4h, after the end of CPB. Compared to prior CPB, the mean red blood cell count of gastric secretion and serum gastric level were significantly descent (Plt;0.01) in all there group post CBP. Compare to the control group, the mean gastric pH level in group A was significantly elevated at all time intervals post CBP; while the mean gastric secretin red blood cell count was significantly decreased. The mean serum level in group A 30 min post CBP was significantly lower than that in group B and the control group. Compared to the control group, the mean gastric pH level was significantly lower in group B but returned to the pre-CPB level in 24 h. The mean gastric secretin red blood cell amount and serums gastric level in group B at all time intervals were significantly decreased compare to those of the control group. Conclusion Thoracoscopic heart surgery of children with CPB

Clinical Trial of Efficacy of Triple Therapy of Pantoprazo le in Treatment of Duodenal Ulcer

Objective　To investigate the efficacy of pantoprazole and omeprazole as part of triple therapy in treatment of duodenal ulcer. Methods　Seventy-eight patients with duodenal ulcer and HP-positive were randomized to two groups. A random number table was used to generate random sequence. The sequence was not concealed. No blinding was used. Thirty-nine patients received pantoprazole 40 mg + amoxicillin 1.0 g + clarithromycin 0.5 g (PAC group) and 39 patients received omeprazole 20 mg + amoxicillin 1.0 g + clarithromycin 0.5 g (OAC group), twice daily with duration of 7 days. The follow-up time was 4 to 6 weeks. Results　At the end of the treatment, 38 patients completed the study, and 1 patient lost to follow-up in the PAC group; thirty-seven patients completed the study, two patients lost to followup in the OAC group. The results of intention-to-treat analysis and per-protocol analysis showed that the HP eradication rates were 87.2%/89.5% in the PAC group and 87.2%/91.9% in the OAC group (P＞0.05); the clinical improvement rates were 79.4%/81.6% in the PAC group and 82.0%/86.5% in the OAC group (P＞0.05). The side effect rates were 10.6% in the PAC group and 8.1% in the OAC group (P＞0.05). No significant difference was found between the two groups (P＞0.05). Conclusions　The PAC group is therapeutically effective for eradication of HP and improves symptoms and has an equivalent effect to OAC group for patients with HP-positive duodenal ulcer. Both drugs are well tolerated.

The Clinical Efficacy of Kangfuxin Liquid plus Omeprazole for Gastric Ulcer

目的　探讨康复新液联合奥美拉唑三联疗法治疗幽门螺杆菌（Hp）阳性的胃溃疡的临床疗效和内镜下溃疡愈合情况。 方法　将2010年1月－2012年1月对住院及门诊180例内镜诊断并检测证实Hp阳性的胃溃疡患者，按计算机产生的随机数字表随机分为两组，每组各90例。两组均给予口服奥美拉唑20 mg，2次/d，克拉霉素0.5 g，2次/d，甲硝唑0.4 g，2次/d，铝碳酸镁1.0 g，3次/d，治疗7 d。7 d后改为口服奥美拉唑20 mg，1次/d，铝碳酸镁1.0 g，3次/d，疗程4周，治疗组加服康复新液10 mL，3次/d；对照组不使用康复新液。治疗期间以上腹痛作为判断症状改善的主要指标，疗程结束后复查胃镜观察溃疡愈合情况，同时观察药物不良反应。 结果　治疗组在临床症状改善总有效率93.3%，对照组为总有效率82.2%；溃疡病灶愈合方面治疗组总有效率94.4%，对照组为总有效率83.3%，两组比较有统计学意义（P＜0.05），临床应用4周后无任何不良反应，Hp根除率两组间差异无统计学意义。 结论　康复新液联合奥美拉唑三联疗法可有效治疗胃溃疡，治疗期间患者未发生不良反应，为治疗胃溃疡的一种安全有效的药物。

不同剂量奥美拉唑治疗消化不良的疗效观察

【摘要】　目的　评价不同剂量奥美拉唑治疗功能性消化不良的疗效及安全性。　方法　选择2010年3月-2011年6月门诊就诊的120例功能性消化不良患者，随机分为两组，小剂量组（60例）口服奥美拉唑10 mg，1次/d；常规剂量组（60例）口服奥美拉唑20 mg，1次/d。疗程均为4周。观察两组患者反酸、上腹痛、嗳气、餐后饱胀、气胀、呕吐等临床症状的改善程度。　结果　小剂量组与常规剂量组总有效率比较差异无统计学意义（Pgt;0.05），但显效率差异有统计学意义（Plt;0.05）， 常规剂量组治疗后反酸、上腹痛、餐后饱胀、气胀症状积分改善明显优于小剂量组。两组不良反应均较轻微。　结论　常规剂量奥美拉唑对治疗功能性消化不良的反酸、餐后饱胀、上腹痛和气胀等临床症状的改善尤其明显，不良反应少，效果佳。

雷贝拉唑与奥美拉唑治疗幽门螺杆菌阳性消化性溃疡的临床比较

【摘要】 目的 比较雷贝拉唑与奥美拉唑三联疗法治疗幽门螺杆菌（helicobacter pylori，Hp）阳性消化性溃疡的临床疗效。 方法 2009年1-12月将96例Hp阳性的消化性溃疡及慢性胃炎患者，根据治疗方法不同随机分为雷贝拉唑组（52例）和奥美拉唑组（44例）。两组联合的抗菌药均为克拉霉素和阿莫西林，疗程1周。各组在治疗后4～8周分别检测Hp感染情况，并观察溃疡的愈合情况。 结果 雷贝拉唑组Hp根除率及3 d症状缓解率分别为96.2%（50/52）、82.7%（43/52），奥美拉唑组分别为88.6%（39/44）、72.7%（32/44），雷贝拉唑组均明显高于奥美拉唑组（Plt;0.05）。雷贝拉唑组溃疡愈合率为98.1%（51/52），与奥美拉唑组的95.5%（42/44）比较无统计学意义（Pgt;0.05）。 结论 雷贝拉唑联合克拉霉素和阿莫西林是根除Hp比较有效的一种治疗方案。

钠钾镁钙葡萄糖注射液与注射用奥美拉唑钠存在配伍禁忌一例

Efficacy of esomeprazole versus omeprazole in the treatment of non-variceal gastrointestinal bleeding: a meta-analysis

ObjectivesTo systematically review the efficacy and safety of esomeprazole versus omeprazole in the treatment of acute non-variceal upper gastrointestinal bleeding (ANVUGIB).MethodsPubMed, EMbase, The Cochrane Library, CNKI, WanFang Data and VIP databases were electronically searched to collect the randomized controlled trials (RCTs) about the efficacy and safety of esomeprazole versus omeprazole in the treatment of ANVUGIB from inception to January, 2019. Two reviewers independently screened literature, extracted data and assessed the risk of bias of included studies, then, meta-analysis was performed by using RevMan 5.3 software.ResultsA total of 17 RCTs involving 2 086 patients were included. The results of meta-analysis showed that, the total effective rate of esomeprazole group was higher than omeprazole group (RR=1.09, 95%CI 1.04 to 1.14, P=0.000 6), the incidence of adverse reactions was lower than omeprazole group (OR=0.27, 95%CI 0.18 to 0.40, P<0.000 01), the average hemostasis time was shorter than omeprazole group (MD=−0.64, 95%CI −0.94 to −0.34, P<0.0001), and the difference were statistically significant.ConclusionsCurrent evidence shows that in the treatment of ANVUGIB, esomeprazole has rapid hemostasis, significant effect and fewer adverse reactions, which is worthy of wide application and promotion. Due to limited quality and quantity of the included studies, more high-quality studies are required to verify the above conclusions.